AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

These are some of the treatments your doctor may have recommended to manage your nasal polyps. The first-line treatment is medication management, typically with nasal steroid sprays like ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

An excellent white T-shirt should be the following: comfortable, durable, flattering, and, of course, versatile. That can be surprisingly hard to find — so as one of the Strategist’s writers ...

Asthma and Antibiotic Use May Predict Nasal Polyp Recurrence After Endoscopic Sinus Surgery Feb. 4, 2025 — The probability of revision sinus surgery including the removal of nasal polyps is ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

A 48-year-old woman reported a 1-year history of breathlessness, persistent cough and recurrent chest infections. She was a former smoker with a medical history of nasal polyps and asthma since ...

As one of our resident wardrobe-basics experts, I’ve learned that a good white T-shirt is easy to find, but a truly great one — one that hits the marks on comfort and durability as well as ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...